Neurocrine Biosciences, Inc. (NBIX) Stock Score, Valuation & Financial Research
Neurocrine Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 55/100.
Quick answer for NBIX
Neurocrine Biosciences, Inc. currently has a Wall Street Score of 55/100. The stored market price is $149.5. Its financial score is 33/100. Its valuation score is 44/100. These figures are a research snapshot, not a buy or sell recommendation.
What Neurocrine Biosciences, Inc. does
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-men
NBIX financial snapshot
- Wall Street Score:
- 55/100
- Current price:
- $149.5
- Market capitalization:
- $15.03B
- Revenue:
- $3.10B
- Net income:
- $668.6M
- Free cash flow:
- $748.7M
- Cash:
- $266.5M
- Total debt:
- $406.2M
- EPS:
- 4.81
- P/E ratio:
- 31.1x
- Financial score:
- 33/100
- Valuation score:
- 44/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $748.7M, showing positive cash generation.
- The balance sheet shows $266.5M of cash versus $406.2M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 44/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 33/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NBIX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.